Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
Merck (MRK) and Daiichi Sankyo withdrew their accelerated approval request for the lung cancer drug ifinatamab deruxtecan (I-DXd) after the FDA found the data insufficient. The FDA indicated the data did not meet criteria for the proposed indication. Merck and Daiichi continue Phase 3 trials for I-DXd in other cancers. Analysts note this is a setback for Merck but a potential opportunity for competitors GSK (GSK) and Roche (RHHBY).
How this was made
The 30-second read
Why it matters
Regulatory rejection removes near‑term upside from the ADC, likely prompting short‑term sell pressure while longer‑term trial data remain pending.
Market read
Regulatory news for a major oncology asset, immediate price impact for two listed pharma stocks.
What to watch
The companies continue Phase 3 trials; a future filing could restore confidence, and the FDA hold was lifted earlier this year.
Background
Merck and Daiichi Sankyo had been pursuing accelerated approval for I‑DXd in extensive‑stage small cell lung cancer, a high‑need indication.
Ticker impact
Merck withdrew its FDA accelerated‑approval application for the I‑DXd lung‑cancer ADC after the agency said data were insufficient.
downward pressure as investors price in the lost approval opportunity
Regulatory rejections for late‑stage ADCs historically trigger share declines; Merck's large‑cap status amplifies market reaction.
Market effects
Setback may shift investor focus to competing ADC programs from GSK and Roche, potentially boosting their stocks.
US biotech and pharma stocks could see heightened volatility as regulators scrutinize ADC data packages.
Moderate, as the decision influences global oncology pipeline expectations.
Counterpoint
If the Phase 3 data later prove compelling, the withdrawal could be seen as a temporary hurdle, offering a buying opportunity at a discount.
Key entities
- CompanyMerck
Large‑cap pharma, ticker MRK
- CompanyDaiichi Sankyo
Japanese pharma partner, ticker DSK
